




**Paolo Galfetti**  
CEO

- Company Overview
- APR Successful Ventures
  - As Developer and Licensor
  - As Investor
  - As Service Provider
- APR R&D Pipeline
- Partnering Opportunities
- Conclusions

- Founded: 1990 as a private independent Swiss Corporation but became operative in 2000 only.
- Headquartered in Balerna (Lugano - Switzerland) with a fully owned subsidiary in Charlotte, NC (Applied Pharma Research USA, LLC).



- Top Line Revenues 2008: USD 14.42 Mio
- EBDTA 2008: USD 3.02 Mio
- Debt Free and Cash Positive

- Expected steadily growth thanks to projects close to fruition.
- Experienced and Talented Board of Directors and Management Team

APR is a private, independent, vertically integrated R&D company in Healthcare.

APR strategic approach to Product R&D is pursued through the combined:



**(a) Development and license of added value, proprietary products and oral and topical drug delivery technologies**

**(b) Investment into companies or projects synergic to APR business model, and provide capital and know how**

**(c) Supply of added value consultancy, R&D and regulatory services in EU and US with a one stop shop approach**

As Developer and Licensor:  
Globally Developed and out-licensed added value products and technologies based on proprietary oral and topical drug delivery systems

- Several Rx and OTC approved/marketed/partnered proprietary products
- Licensing Agreements in 117 countries\*  
(including US, EU, China)
- Strong R&D Pipeline

## Leading Rx Products

- 1<sup>st</sup> Immediate Release Technology (IRT) diclofenac formulation NDA approved by FDA (June 2009) for Migraine attacks.
- Approved and marketed in over 30 countries ex-US.
- Bridging the gap between OTC and Triptans (safe first line of therapy).
- Demonstrated rapid onset within 15-20 min. (fastest acting)



- Second generation matrix pain patch
- Approved and marketed in 1 EU country.
- In Phase III development in US and remaining EU



- Innovative Film Strip Technology applied to Rx products only
- Ondansetron Film Strip 4 and 8 mg
- Licensed in Europe, North America and Far East
- Expected Approval in either EU and US during Q1/2010

## Leading OTC Products



- Decongestant Patch (safe and AEs free)
- Four natural essential oil formulations with and without camphor and “no-chew” bittering agent
- Marketed in over 20 countries ex-US.
- US launch Q4/2009
- 8 hours duration

- Petroleum free, not messy, hygienic Decongestant of the air passages cream formulation in Roll-on Stick
- Approved and marketed in over 10 countries ex-US.



As Investor:

Investment into selected Healthcare Companies and provide capital funding as well as R&D Know How



Service and consulting company offering business development and transaction services (in & out licensing, asset acquisition and divestments, company merger and acquisitions) on a global basis.

## APR Nanotech s.a.

R&D company focused on the development of bio products through use of a patented nanotechnology process. The first lead candidate for topical use has proven anti infective properties without creating antibiotic resistance.



As Service Provider:  
Added value consultancy, R&D and regulatory services  
in EU and US with a one stop shop approach

In the Service Business we are primarily focused on:

- Development of third party projects with or without using our own proprietary oral and topical drug delivery technologies;
- Development of “critical generics”, product life cycle management, formulation improvement, etc.
- Strategic and Regulatory Consultancy (EU ↔ US)
- Wide client basis (ranging from Big Pharma to small biotech).

- Several RapidFilm formulations based on off patents or soon to expiry Rx active ingredients alone or in combination (primarily targeting CNS disorders).

	PreClinical	Clinical	Dossier	Registr.	Marketed
Ondansetron RapidFilm					
RF002					
RF003					
RF004					
RF005					

- Diclofenac Matrix Patch (for US market and selected EU countries).
- FDA Approved Cambia for selected ex-US countries.
- Fully Stable Acidic Electrolyzed Water (AEW) obtained through a patented Nanotechnology process
- Several third party service projects for the development of Rx and OTC with partnership option


# RapidFilm Tech. & Ondansetron



## RapidFilm Technology

Novel, patented, non-mucoadhesive, fast dissolving, oral delivery system based on a water soluble polymer: placed on top of the tongue, the film disperses within seconds.

Non substitutable,  
differentiated product  
to be approved as  
505(b)2 NDA



<b>NO SWALLOWING DIFFICULTIES</b>	<b>Better patient compliance</b> It is estimated that 25% of the population find the swallowing of tablets and capsules difficult and therefore do not take their medication as prescribed, resulting in ineffective therapy.
<b>IT CAN NOT BE SPIT OUT</b>	<b>Ideal for paediatric and geriatric use</b>
<b>NO LIQUID NECESSARY FOR INTAKE</b>	<b>"Take away" medicine</b>
<b>VERY SLIM FORMAT</b>	<b>Can be carried in the wallet</b>

**RAPIDFILM TECHNOLOGY COMBINES THE BENEFITS OF LIQUID DOSAGE FORMS (easy administration) AND OF SOLID DOSAGE FORMS (exact secure dosing)**

## 100% Bio Product through Nanotechnology

The APR patented nano-coating process resolved the stability issue of common Electrolyzed Water opening potentially revolutionary opportunities of application in several fields:

### PROVEN APPLICATIONS

**Unique formulation able to kill bacteria and pathogens within seconds without creating antibiotic resistance**

Acidic Electrolyzed Water (AEW) is a well-known highly effective disinfectant for either humans and environment but all currently available products are unstable; APR patented technology enabled production of fully stable AEW, avoiding the need to have on-site machinery.

### UPSIDE POTENTIAL

By mimicking production of our body's antimicrobial agents by our immune system, our product could be potentially used (tests and trials are ongoing) in different areas with high revenue potential such as:

- **Healthcare**
  - Dermatology
  - Ophthalmology
  - Gynecology
  - Wound Healing
  - Immune-related diseases
- **Cosmetic**
  - Lenitive and Moisturizing Properties with potential for several applications
  - Improved absorption of select actives



- In/out Licensing
  - Extensive pipeline of marketed and late stage development Rx and OTC products available for licensing out in major markets;
  - We are seeking to in-license, acquire or invest into new innovative products /projects
  - Seeking partners for APR Nanotechnology project
- Service Provider
  - Wide range of oral and topical drug delivery technologies
  - We can support companies to:
    - Improve product formulation and extend /renovate product life cycle
    - Achieve Global development and out-licensing reach
    - Expand Product Portfolio

- Innovative business model: we merge in one company know how and competencies typical of different players in Healthcare;
- Innovative Drug Delivery platforms and technologies and late stage product development portfolio
- Low Risk profile: wider approach for a higher success (vertically integrated, 3 business areas, geographical reach)
- Extensive R&D pipeline of proprietary, self funded projects for out-licensing;
- Seeking to in-licensing/acquire additional innovative projects;

# Q&A

## Contact information:

APR s.a. – Lugano, Switzerland

Paolo Galfetti

CEO

[paolo.galfetti@apr.ch](mailto:paolo.galfetti@apr.ch)

Tel +41-091-6957020

APR USA – Charlotte, NC

Aldo Donati

Vice President

[aldo.donati@apr.ch](mailto:aldo.donati@apr.ch)

Tel (704) 365-3232

[www.apr.ch](http://www.apr.ch)



**Healthcare Conference**

New York, September 9 – 10, 2009